Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide plus Docetaxel in First-Line CRPC
NCT02453009Phase 2Completed
- Sponsor
- Santa Chiara Hospital
- Start
- Oct 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by Santa Chiara Hospital. Started Oct 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02453009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453009.